MA39020A1 - Sels de l'acide 1 -(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluorométhyl)-2,3-dihydro-lh-indén-1 -yl]-1,2,3,4-tétrahydropyrimidine-5-carboxylique - Google Patents
Sels de l'acide 1 -(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluorométhyl)-2,3-dihydro-lh-indén-1 -yl]-1,2,3,4-tétrahydropyrimidine-5-carboxyliqueInfo
- Publication number
- MA39020A1 MA39020A1 MA39020A MA39020A MA39020A1 MA 39020 A1 MA39020 A1 MA 39020A1 MA 39020 A MA39020 A MA 39020A MA 39020 A MA39020 A MA 39020A MA 39020 A1 MA39020 A1 MA 39020A1
- Authority
- MA
- Morocco
- Prior art keywords
- dihydro
- salts
- tetrahydropyrimidine
- benzoxazol
- inden
- Prior art date
Links
- -1 3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl Chemical group 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 abstract 1
- 159000000000 sodium salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13192177 | 2013-11-08 | ||
| PCT/EP2014/073801 WO2015067652A1 (de) | 2013-11-08 | 2014-11-05 | Salze von 1 -(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1 -yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39020A1 true MA39020A1 (fr) | 2017-04-28 |
Family
ID=49552231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39020A MA39020A1 (fr) | 2013-11-08 | 2014-11-05 | Sels de l'acide 1 -(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluorométhyl)-2,3-dihydro-lh-indén-1 -yl]-1,2,3,4-tétrahydropyrimidine-5-carboxylique |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9926305B2 (https=) |
| EP (1) | EP3066097B1 (https=) |
| JP (1) | JP6446051B2 (https=) |
| KR (1) | KR102351418B1 (https=) |
| CN (1) | CN105658647B (https=) |
| AP (1) | AP2016009181A0 (https=) |
| AU (1) | AU2014345599B2 (https=) |
| BR (1) | BR112016010253A8 (https=) |
| CA (1) | CA2929780C (https=) |
| CL (1) | CL2016001096A1 (https=) |
| CY (1) | CY1119520T1 (https=) |
| DK (1) | DK3066097T3 (https=) |
| EA (1) | EA033132B1 (https=) |
| ES (1) | ES2645480T3 (https=) |
| HR (1) | HRP20171603T1 (https=) |
| HU (1) | HUE035021T2 (https=) |
| IL (1) | IL245407B (https=) |
| LT (1) | LT3066097T (https=) |
| MA (1) | MA39020A1 (https=) |
| ME (1) | ME02907B (https=) |
| MX (1) | MX366848B (https=) |
| MY (1) | MY190108A (https=) |
| NO (1) | NO3066097T3 (https=) |
| PH (1) | PH12016500853B1 (https=) |
| PL (1) | PL3066097T3 (https=) |
| PT (1) | PT3066097T (https=) |
| RS (1) | RS56509B1 (https=) |
| SA (1) | SA516371082B1 (https=) |
| SI (1) | SI3066097T1 (https=) |
| TN (1) | TN2016000170A1 (https=) |
| UA (1) | UA117686C2 (https=) |
| WO (1) | WO2015067652A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3338780A1 (de) | 2016-12-20 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind |
| WO2018197333A1 (en) * | 2017-04-27 | 2018-11-01 | Bayer Aktiengesellschaft | Selective adrenoreceptor alpha2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad) |
| CN114671856B (zh) * | 2020-12-25 | 2023-10-20 | 广东东阳光药业股份有限公司 | 多取代的尿嘧啶衍生物及其用途 |
| WO2023194222A1 (en) * | 2022-04-05 | 2023-10-12 | Socpra Sciences Santé Humaines S.E.C. | Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4175887B2 (ja) * | 2000-10-19 | 2008-11-05 | 日本化薬株式会社 | 新規血管狭窄治療剤または予防剤 |
| AT511788A1 (de) | 2011-07-29 | 2013-02-15 | Georg Dr Gaul | Vorrichtung zur vorgebbaren anordnung eines stents |
| JP6549376B2 (ja) * | 2012-03-05 | 2019-07-24 | グラタク テクノロジーズ ピーティーワイ リミテッド | 栄養補助食品 |
| UA112897C2 (uk) * | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
| HK1224288A1 (zh) * | 2013-11-08 | 2017-08-18 | Bayer Pharma Aktiengesellschaft | 作为类糜蛋白酶抑制剂的取代的尿嘧啶 |
-
2014
- 2014-11-05 CN CN201480057947.4A patent/CN105658647B/zh active Active
- 2014-11-05 BR BR112016010253A patent/BR112016010253A8/pt not_active Application Discontinuation
- 2014-11-05 ME MEP-2017-249A patent/ME02907B/me unknown
- 2014-11-05 NO NO14793565A patent/NO3066097T3/no unknown
- 2014-11-05 DK DK14793565.4T patent/DK3066097T3/da active
- 2014-11-05 UA UAA201606202A patent/UA117686C2/uk unknown
- 2014-11-05 MA MA39020A patent/MA39020A1/fr unknown
- 2014-11-05 CA CA2929780A patent/CA2929780C/en active Active
- 2014-11-05 SI SI201430450T patent/SI3066097T1/sl unknown
- 2014-11-05 EA EA201600381A patent/EA033132B1/ru not_active IP Right Cessation
- 2014-11-05 US US15/035,165 patent/US9926305B2/en active Active
- 2014-11-05 WO PCT/EP2014/073801 patent/WO2015067652A1/de not_active Ceased
- 2014-11-05 RS RS20171063A patent/RS56509B1/sr unknown
- 2014-11-05 AP AP2016009181A patent/AP2016009181A0/en unknown
- 2014-11-05 LT LTEP14793565.4T patent/LT3066097T/lt unknown
- 2014-11-05 PL PL14793565T patent/PL3066097T3/pl unknown
- 2014-11-05 AU AU2014345599A patent/AU2014345599B2/en active Active
- 2014-11-05 ES ES14793565.4T patent/ES2645480T3/es active Active
- 2014-11-05 JP JP2016551038A patent/JP6446051B2/ja active Active
- 2014-11-05 MY MYPI2016701615A patent/MY190108A/en unknown
- 2014-11-05 KR KR1020167011771A patent/KR102351418B1/ko active Active
- 2014-11-05 HU HUE14793565A patent/HUE035021T2/en unknown
- 2014-11-05 MX MX2016005971A patent/MX366848B/es active IP Right Grant
- 2014-11-05 EP EP14793565.4A patent/EP3066097B1/de active Active
- 2014-11-05 TN TN2016000170A patent/TN2016000170A1/en unknown
- 2014-11-05 HR HRP20171603TT patent/HRP20171603T1/hr unknown
- 2014-11-05 PT PT147935654T patent/PT3066097T/pt unknown
-
2016
- 2016-05-01 IL IL24540716A patent/IL245407B/en active IP Right Grant
- 2016-05-06 PH PH12016500853A patent/PH12016500853B1/en unknown
- 2016-05-06 CL CL2016001096A patent/CL2016001096A1/es unknown
- 2016-05-08 SA SA516371082A patent/SA516371082B1/ar unknown
-
2017
- 2017-10-25 CY CY20171101110T patent/CY1119520T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34545B1 (fr) | Co-cristaux et sels d'inhibiteurs de ccr3 | |
| MA42109B1 (fr) | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase | |
| MA38175A1 (fr) | Lactames fusionnés à un aryle et hétéroaryle | |
| MA41238B1 (fr) | Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit | |
| MA40219A (fr) | Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide | |
| MA38999A1 (fr) | Nouveaux composés hétérocycliques | |
| MA35749B1 (fr) | Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc | |
| JO3781B1 (ar) | مشتقات الكينولون | |
| UA104489C2 (uk) | Сполуки для лікування дисліпідемії та споріднених хвороб | |
| EA201200918A1 (ru) | Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений | |
| MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| MA37647A1 (fr) | Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci | |
| MA39020A1 (fr) | Sels de l'acide 1 -(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluorométhyl)-2,3-dihydro-lh-indén-1 -yl]-1,2,3,4-tétrahydropyrimidine-5-carboxylique | |
| MA35268B1 (fr) | 1-pipérazino-3-phénylindanes deutérés pour le traitement de la schizophrénie | |
| MA38679B1 (fr) | Modulateurs du récepteur de cxcr7 | |
| MA44965A (fr) | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 | |
| MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
| MA38857B1 (fr) | Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone | |
| EA201990550A1 (ru) | Офтальмологический препарат, включающий азоловое соединение | |
| MA38307B1 (fr) | 4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale | |
| MA39533B1 (fr) | Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives | |
| EP2933254A4 (en) | NOVEL COMPOUND, PHARMACEUTICALLY COMPATIBLE SALT AND OPTICAL ISOMER THEREOF, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF VIRUS DISEASES THEREFOR AS AN ACTIVE SUBSTANCE | |
| EP2862573A4 (en) | COMPOSITION FOR THE TREATMENT OR PROPHYLAXIS OF VASER SPERMABILITY-RELATED DISEASES WITH IMATINIB OR PHARMACEUTICAL ACCEPTABLE SALT AS AN ACTIVE SUBSTANCE | |
| EP2543374A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF OSTEOARTHRITIS WITH REBAMIPID AS AN ACTIVE SUBSTANCE | |
| EP2822899A4 (en) | METHOD FOR PRODUCING BIOCIDAL AND ABSORBENT PREVALENT AQUEOUS COMPOSITIONS WITH BROMINE HYDROGEN, UREA, AND SODIUM HYPOCHLORITE |